BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has won another legal case against Miltenyi Biotec in the Cologne Regional Court, Germany, regarding the unauthorized reverse engineering of Bio-Techne's proprietary NKG2C/CD159c antibodies. The court found that Miltenyi's antibodies had 100% identical variable regions to Bio-Techne's R&D Systems branded products.

This victory follows a similar 2023 case where Miltenyi was found to have reverse engineered Bio-Techne's TIGIT and CCR-7 antibodies. The court has awarded Bio-Techne monetary damages for sales of the reverse engineered antibodies, reimbursement of costs for demonstrating copying, and rights to additional information about Miltenyi's unlawful activities. Miltenyi retains the right to appeal the ruling.

Positive

• Court victory grants Bio-Techne monetary damages for unauthorized antibody sales
• Court awards reimbursement of costs for proving intellectual property infringement
• Company gains right to detailed information about Miltenyi's reverse engineering activities

Negative

• Potential appeal by Miltenyi could extend legal proceedings
• Ongoing intellectual property violations indicate continued market competition risks

MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.  

Bio-Techne took legal action against Miltenyi in the Cologne Regional Court, Germany (docket no. 33 O 221/24), after discovering that the variable regions of Miltenyi's NKG2C/CD159c antibodies were 100% identical to the R&D Systems antibodies. In addition to finding that Miltenyi has been marketing and selling these reverse engineered antibodies, the court determined that Bio-Techne is entitled to monetary damages related to sales of the reverse engineered antibodies, reimbursement for Bio-Techne's costs incurred to demonstrate that Miltenyi copied our antibodies and additional detailed information regarding Miltenyi's unlawful reverse engineering activities.

"We are pleased the court has recognized that Miltenyi has repeatedly and unlawfully passed off Bio-Techne's proprietary innovations to Miltenyi's customers as their own," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "We have spent almost five decades developing our extensive catalogue of solutions that enable the scientific community to discover novel biological insights and develop advanced therapeutics. We will continue to vigorously defend our intellectual property against Miltenyi and any other potential offenders."

Miltenyi may appeal the Court's ruling.

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

Contact:

David Clair, Vice President, Investor Relations & Corporate Development david.clair@bio-techne.com 612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-successful-on-second-claim-of-reverse-engineering-by-miltenyi-biotec-302343926.html

SOURCE Bio-Techne Corporation

FAQ

What was the outcome of Bio-Techne's (TECH) latest legal case against Miltenyi Biotec?

Bio-Techne won the case in Cologne Regional Court, proving Miltenyi unlawfully reverse engineered their NKG2C/CD159c antibodies, and was awarded monetary damages and cost reimbursement.

How many legal victories has Bio-Techne (TECH) secured against Miltenyi for reverse engineering?

Bio-Techne has secured two legal victories against Miltenyi, one in 2023 for TIGIT and CCR-7 antibodies, and another in 2025 for NKG2C/CD159c antibodies.

What compensation will Bio-Techne (TECH) receive from the 2025 Miltenyi court ruling?

Bio-Techne will receive monetary damages from antibody sales, reimbursement for costs to prove copying, and access to detailed information about Miltenyi's reverse engineering activities.

Which Bio-Techne (TECH) antibodies did Miltenyi Biotec illegally reverse engineer in the 2025 case?

Miltenyi Biotec illegally reverse engineered Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies.